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Neurodegenerative diseases are a very diverse group of disorders but they share some common mech-
anisms such as abnormally misfolded proteins with prion-like propagation and aggregation. Creutzfeldt-
Jakob disease (CJD) is the most prevalent prion disease in humans. In the sporadic form of CJD the only
known risk factor is the codon 129 polymorphism. Recent reports suggested that a-synuclein in multiple
system atrophy (MSA) has similar pathogenic mechanisms as the prion protein. Here we present 1 Italian
family with MSA and prion disease. Also, cases of concurrent MSA and prion pathology in the same
individual or family suggest the possibility of molecular interaction between prion protein and a-syn-
uclein in the process of protein accumulation and neurodegeneration, warranting further investigations.
We assessed the PRNP gene by whole-exome sequencing in 264 pathologically conﬁrmed MSA cases and
462 healthy controls to determine whether the 2 diseases share similar risk factors. We then analyzed
codon 129 polymorphism by Sanger sequencing and compared with previously published results in
sporadic CJD. Homozygosity at codon 129 was present in 50% of pathologically conﬁrmed MSA cases and
in 58% of normal controls (odds ratio, 0.7 (95% conﬁdence interval of 0.5e0.9)) compared with 88.2% in
sporadic CJD. Our data show that the homozygous state of position 129 in the PRNP is not a risk factor for
MSA. No other variants in the PRNP gene were associated with increased risk for MSA.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Neurodegenerative diseases represent a signiﬁcant cause of
disability and life span reduction worldwide (Bird et al., 2003;
Huisman et al., 2011; Pringsheim et al., 2014). They are a very
diverse group with a wide variety of symptoms, but they share
some common pathogenic mechanisms such as abnormally mis-
folded proteins that accumulate in neurons or glia. A second com-
mon hallmark of many neurodegenerative diseases is the prion-likeintervals, CI; cytoplasmic
dic Creutzfeld-Jakob disease,
ueen Square, London WC1N
5616.
Inc. This is an open access articlemechanism of propagation and aggregation of these misfolded
proteins.
Prion diseases are a group of fatal neurodegenerative conditions
caused by the accumulation of abnormally folded prion protein (PrP).
They can be classiﬁed as acquired, inherited, or sporadic. Sporadic
Creutzfeld-Jakobdisease (sCJD) is thecommonesthumanpriondisease.
Multiple system atrophy (MSA) is a rapidly progressing neuro-
degenerative disorder with late onset and poor prognosis. Although
the exact mechanisms behind MSA are not entirely elucidated; the
neuropathological hallmark of the disease is the accumulation of
abnormally folded a-synuclein (a-syn) and the pathognomonic
formation of glial cytoplasmic inclusions (Ahmed et al., 2012;
Wenning et al., 2008). MSA is mainly a sporadic disease but a few
familial cases with Mendelian inheritance have been reported
(Hara et al., 2007; Wullner et al., 2004). However, no causal gene
was identiﬁed in those families.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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between prion disease PrP and MSA a-syn protein misfolding,
propagation and self-aggregation (Woerman et al., 2015), raising
the question that these disorders might involve joint risk factors. So
far, the only risk factor associated with sCJD is older age and a
polymorphism in the host’s prion gene locus PRNP at codon 129
(rs1799990); results conﬁrmed in a Genome Wide Association
Study (Mead et al., 2012). Unique to humans, this polymorphic site
can either encode a methionine (M) or a valine (V) resulting in 3
possible genotypes: M129M, M129V and V129V. A large study
including 300 patients showed that almost 90% of all sCJD cases
were homozygous at codon 129 with the largest group presenting
the M129M genotype (Parchi et al., 1999). For sCJD, the heterozy-
gous state M129V appears to be protective against the disease,
whereas the homozygous M129M and V129V genotypes carry
increased risk for all forms of prion diseases suggesting that the
genotype of PRNP at codon 129 inﬂuences the susceptibility and the
phenotype of the sCJD (Mead et al., 2012). Recent data also conﬁrm
that the M/V 129 residue has a crucial role in prion protein aggre-
gation (Skora et al., 2013).
The 129 codon PRNP polymorphism status has not been previ-
ously assessed in large MSA studies but was reported in a case of a
64-year-old patient, who developed sporadic prion disease 4 years
after being diagnosed with MSA. The genotype in this case was
M129M homozygous for PRNP (Shibao et al., 2008).
Here, we report an unusual co-occurrence of prion disease and
MSA in 1 Italian family. In a pedigree of genetically conﬁrmed
Gerstmann-Sträussler-Scheinker syndrome, MSA developed in an
individual negative for the pathogenic mutation. Given the recent
reports of prion-like mechanisms in MSA and cases of associated
MSA and prion pathology, we conducted a study to assess whether
variants in PRNP and in particular the polymorphism status at
codon 129 of PRNP gene represents a risk factor for MSA.
2. Methods
2.1. Subjects and genetic analysis
We have investigated by whole-exome sequencing that 264
pathologically conﬁrmed MSA cases of Caucasian ethnicity from
MSA Brain Bank and DNA Collaboration (see Acknowledgements).
MSA-C, MSA-P, and combined MSA-P/C cases were included. DNA
was extracted frombrain tissue using a standard technique followed
by next generation sequencing (Singleton et al., 2010). Whole-
exome sequencing data were obtained from 462 healthy controls
of Caucasian origin older than 65 whowere conﬁrmed postmortem
to be neuropathologically normal from the Healthy Exomes data-
base. Quality control of exome data included removal of samples
with highmissingness rate, excess heterozygosity, sex check failure,
or evidence of cryptic relatedness. To assess ancestry from exomeTable 1
PRNP coding variants found in our pathologically conﬁrmed MSA cohort
Variant Type of mutation
rs138688873 c.246_269delACAGCCTCATGGTGGTGGCTGGGG
p.Pro84_Gln91del
inframe deletion
rs201423990 c.372C>G synonymous
rs1799990
c.385A>G p.M129V
missense
rs150351644
c.424G>A
p.G142S
missense
Key: OR, odds ratio; MSA, multiple system atrophy.
Total observed alleles-calculated as 2 chromosomes per individual.data, we identiﬁed a set of pruned, common SNPs (minor allele
frequency>0.05), and extracted the same SNPs from all populations
in 1000 Genomes Project phase 3 data. We then merged MSA,
control, and 1000 Genomes data and performed principal compo-
nent analysis, using the software package PLINK v.1.9. The ﬁrst,
second, and third principal components were used to visualize
ancestry in plots and outliers were removed, leaving only samples
that clustered together with the Caucasians in the ﬁnal data set.
We also investigated by Sanger sequencing the PRNP 129 poly-
morphism in 238 of the pathologically conﬁrmed MSA cases. PRNP
PCR primers designed to span the region of interest (M129V poly-
morphism, rs# cluster id 1799990) and about 50 bp of ﬂanking coding
sequence (50CTGGGGTCAAGGAGGTGG 30and 50 AACGGTGCATGTTTT-
CACGA 30). The variant was PCR ampliﬁed using intronic primers. The
puriﬁed PCR product was sequenced bi-directionally with Big Dye
Terminator Kit v.3.1 (Applied Biosystems). Sanger sequencing was
performed using a conventional protocol described elsewhere
(Houlden et al., 2001). PRNP variant position is based on NCBI refer-
ence sequences: NM_000311, NP_000302 (www.ncbi.nlm.nih.gov).
Brain tissue obtained from QSBB was donated for research using
ethically approved protocols and stored under a license from the
HumanTissue Authority. DNAwas extracted and investigated under
approval of the joint ethics committee of UCL Institute of Neurology
and the National Hospital for Neurology and Neurosurgery, London,
UK (UCLH: 04/N034).
We investigated in ourMSA clinic one family with bothMSA and
prion pathology.
2.2. Statistical analysis
Odds ratios and 95% conﬁdence intervals were calculated to
assess the association between PRNP variant in MSA versus control
andMSA versus sCJD. We used published genotype data for the sCJD
froma cohort of 300 cases (Parchi et al.,1999). Thec2 testwas used to
assess p value; 2-tailed p  0.05 was the signiﬁcance level used for
statistical analysis.We used the SPSS software for statistical analysis.
3. Results
3.1. PRNP genotype in MSA cases
After sequencing the whole PRNP gene we found no pathogenic
mutation in ourMSAcases. Therewere 4 coding variants in the PRNP
with codon 129 polymorphism being the most frequent (Table 1).
Detailed analysis of the codon 129 polymorphism by Sanger
sequencing showed that 129 homozygous variant was present in
50% of the 238 pathologically conﬁrmed MSA cases (119 cases,
37.82% of M129M and 12.18% of V129V). The comparable ﬁgures
were 58% in normal controls (OR 0.7; 95% CI of 0.5e0.9) and 88.2%
in sCJD (OR 0.13 and p < 0.0001; Table 2).Status Total nonreference
alleles
Total observed
alleles
Allele
frequency
OR P
MSA 3 525 0.0057 0.74 0.54
Controls 7 913 0.0076
MSA 2 424 0.0047 1.08 NA
Controls 4 920 0.0043
MSA 200 528 0.38 0.7 0.04
Controls 295 924 0.32
MSA 1 528 0.0019 NA NA
Controls 0 924 0
Table 2
PRNP codon 129 genotype distributions within our multiple system atrophy (MSA) group, healthy controls, and sporadic Creutzfeld-Jakob disease (sCJD)
Genotype MSA Controls sCJDa MSA vs controls
Odds ratio (95% CI) p value
M129V heterozygous 119 (50%) 191 (41.4%) 35 (11.8%) 0.7 (0.5e0.9) p ¼ 0.03
M129M and V129V homozygous 119 (50%) 271 (58.6%) 265 (88.2%)
Key: CI, conﬁdence interval.
a - (Parchi et al., 1999).
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The family is originally from Sicily. The male proband is the
eldest of a siblingship of 5 from nonconsanguineous parents. Their
mother, a maternal uncle, maternal grandfather, 2 of his brothers,
and 1 sister have been diagnosed with the hereditary prion disease
Gerstmann-Sträussler-Scheinker syndrome caused by P102L mu-
tation (Fig. 1E). His deceased father was diagnosed with Parkin-
sonism later in life but no ﬁnal diagnosis was reached at the time.
The proband started developing cerebellar ataxia at the age of 55.
The symptoms progressed rapidly and 2 years later, the neurolog-
ical examination revealed progressive ataxia, dysarthria, jerky
pursuit, and hypometric saccades with downbeat nystagmus,
dysphagia, mild bradykinesia, increased tone in the lower limbs,
neurogenic bladder and bowel, autonomic failure and REM sleep
behavior disorder. He had a stooped posture with small steps,
shufﬂing gait and poor arm swing. A levodopa trial made his bal-
ance and orthostatic symptoms worse. BrainMRI conducted 3 years
after disease onset showed marked global cerebellar and brainstem
atrophy with cross-pontine signal change (Fig. 1C and D). FDG PET
of brain and body scan showed cerebellar hypometabolism. This
patient was negative for the familial P102L mutation, SCA panel
genes, and FXTAS. He was diagnosed clinically with MSA.
4. Discussion
In this study, we assessed the PRNP genotypewith a focus on the
polymorphism status at codon 129 of PRNP gene as a risk factor for
MSA in 264 pathologically conﬁrmed MSA cases. Given the recentFig. 1. MRI results for the proband. (A, B): T1 sagittal and T2 transversal view in 2008 at
transversal views 3 years later. Cerebellar atrophy (blue arrow) had progressed and additiona
E. Pedigree demonstrating prion and MSA diseases in the family. The prion-affected cases ar
MSA, multiple system atrophy.reports suggesting that a-syn of MSA has similar pathogenic
mechanisms to the prion PrP in protein misfolding, propagation,
and self-aggregation (Woerman et al., 2015), we assessed whether
they share the same risk factor.
A previous study of 300 cases of sCJD found that M129V poly-
morphism of PRNP was central in determining the susceptibility
and pathologic phenotype in sCJD (Parchi et al., 1999). More spe-
ciﬁcally, heterozygosity at codon 129 is protective against prion
disease (Mead et al., 2012). It is generally believed that the pro-
tective effect of PRNP codon 129 heterozygosity relates to the fact
that misfolded PrP propagation is most effective when the inter-
acting proteins have identical primary structure (Collinge, 2005;
Palmer et al., 1991). Hypothetically, an analogous situation might
exist in synucleinopathies given the existence of common sequence
polymorphisms in the amino acid sequence of a-synuclein, but
coding variants in SNCA are very rare, and associated with auto-
somal dominant Parkinson’s disease (Petrucci et al., 2016). The
co-occurrence of prion disease and MSA, as reported earlier in a
single individual (Shibao et al., 2008) and here in different mem-
bers of a Sicilian family, might suggest the possibility of molecular
interaction between PrP and a-synuclein in the process of protein
accumulation and neurodegeneration, warranting investigation of
the PRNP codon 129 variant in MSA.
Our data show a similar frequency of the heterozygous state
M129V in MSA pathologically conﬁrmed cases compared with the
healthy controls. In contrast to what was previously shown for sCJD,
it appears that the heterozygous state of M129V does not provide
protective effects inMSA, although a larger studywould be required
to unequivocally determine this.onset of MSA symptoms. Only mild cerebellar atrophy was noted. (C, D): sagittal and
l brainstem atrophy with the typical “hot-cross bun sign” had appeared (yellow arrow).
e represented in yellow; the MSA-affected cases are represented in blue. Abbreviation:
V. Chelban et al. / Neurobiology of Aging 49 (2017) 216.e15e216.e18216.e18In many genetic association studies, accurate phenotyping is a
major weakness, particularly when contrasted with the deﬁnitive
nature of genotyping (Shibao et al., 2008). In our study, we have
used pathologically conﬁrmed MSA cases and matched normal
pathologically conﬁrmed cases to ensure accuracy of results.
In conclusion, this is the ﬁrst large study assessing the PRNP gene
and in particular the polymorphism status at codon 129 of PRNP
gene as a risk factor for MSA. Our data show that MSA does not
share the same PRNP 129 locus as a risk factor.
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